Woodcock steps in at CDER as Galson departs

Share this article:
To help it implement new FDA reform legislation signed into law in September, the Bush administration has shaken up the leadership of the agency's drug center, whose flounderings over product safety more than anything else provoked passage of the FDA Amendments Act.

Drug center director Steven Galson was elevated to acting surgeon general.

His predecessor, FDA deputy commissioner and chief medical officer Janet Woodcock, who held the post for over a decade until 2005, has returned to the position on a temporary basis.

Galson's tenure was characterized by major public turbulence on the subordination of drug safety reviews to new drug-approval reviews, which he tried to reverse, the Vioxx and David Graham whistleblower controversy, and the uproar over the Plan B emergency contraceptive OTC switch.
FDA commissioner Andrew von Eschenbach told his employees in an e-mail that a national search for a permanent director for the drug center will begin “immediately.”

Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...